Eric P. Stoffregen

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

Medicine, Oncology, Pharmacology +10

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Amie S. Corbin, Paul La Rosée, Eric P. Stoffregen et al. · Blood · 2003 · 315 citations · Full text

Life Sciences, Molecular Biology, Oncology +9

Activating alleles of JAK3 in acute megakaryoblastic leukemia

Denise K. Walters, Thomas Mercher, Ting-Lei Gu et al. · Cancer Cell · 2006 · 314 citations

Life Sciences, Genetics, Hematology +9

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri et al. · Blood · 2005 · 300 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

Paul La Rosée, Amie S. Corbin, Eric P. Stoffregen et al. · PubMed · 2002 · 204 citations

Medicine, Oncology, Pharmacology +14